Reference : A consensus statement on the European Society for Clinical and Economic Aspects of Os...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/193125
A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - From evidence-based medicine to the real-life setting.
English
Bruyère, Olivier mailto [Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Cooper, C. [> >]
Pelletier, J.P. [> >]
Maheu, E. [> >]
Rannou, F. [> >]
Branco, J. [> >]
Brandi, M.L. [> >]
Kanis, J.A. [> >]
Altman, R.D. [> >]
Hochberg, M.C. [> >]
Martel-Pelletier, J. [> >]
Reginster, Jean-Yves mailto [Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
2016
Seminars in Arthritis and Rheumatism
W.B. Saunders
45
4 Suppl
S3-S11
Yes (verified by ORBi)
International
0049-0172
1532-866X
Philadelphia
PA
[en] glucosamine ; chondroitin ; hyaluronic acid ; knee osteoarthritis ; non-steroidal anti-inflammatory drugs ; symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) ; tramadol
[en] The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis(ESCEO) published a treatment algorithm for the management of knee osteoarthritis (OA) in 2014,which provides practical guidance for the prioritization of interventions. Further analysis of real-world data for OA provides additional evidence in support of pharmacological interventions,in terms of management of OA pain and function, avoidance of adverse events, disease-modifying effects and long-term outcomes, e.g., delay of total joint replacement surgery, and pharmacoeconomic factors such as reduction in healthcare
resource utilization. This article provides an updated assessment of the literature for selected
interventions in OA, focusing on real-life data, with the aim of providing easy-to-follow advice on how to establish a treatment flow in patients with knee OA in primary care clinical practice, in support of the clinicians’ individualized assessment of the patient. In step 1, background maintenance therapy with symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) is recommended, for which high-quality evidence is provided only for the prescription formulations of patented crystalline glucosamine sulfate and chondroitin sulfate. Paracetamol may be added for rescue analgesia only,due to limited efficacy and increasing safety signals. Topical non-steroidal anti-inflammatory drugs (NSAIDs) may provide additional
symptomatic treatment with the same degree of efficacy as oral NSAIDs without the systemic safety concerns. Oral NSAIDs maintain a central role in step2 Advanced management of persistent symptoms.
However, oral NSAIDs are highly heterogeneous in terms of gastrointestinal and cardiovascular safety profile, and patient stratification with careful treatment selection is advocated to maximize the risk: benefit ratio. Intra-articular hyaluronic acid as a next step provides sustained clinical benefit with effects lasting up to 6 months after a short-course of weekly injections. As a last step before surgery, thes low titration of sustained-release tramadol, aweak opioid, affords sustained analgesia with improved tolerability.
http://hdl.handle.net/2268/193125
also: http://hdl.handle.net/2268/194796
10.1016/j.semarthrit.2015.11.010

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
A consensus statement on the European Society for Clinical an Economic Aspects od Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis..pdfPublisher postprint420.53 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.